Advertisement
ACRS vs BNR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACRS is a StrongBuy and BNR is a Hold.
Momentum Indicator for ACRS turns positive, indicating new upward trend
ACRS saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned positive. In 80 of the 92 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ACRS's RSI Indicator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for ACRS just turned positive on October 21, 2026. Looking at past instances where ACRS's MACD turned positive, the stock continued to rise in 35 of 43 cases over the following month. The odds of a continued upward trend are 81%.
Following a +1.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRS advanced for three days, in 224 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ACRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for ACRS entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.525) is normal, around the industry mean (2.973). P/E Ratio (-6.603) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (83.333) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. ACRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Momentum Indicator for BNR turns negative, indicating new downward trend
BNR saw its Momentum Indicator move below the 0 level on October 08, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned negative. In 79 of the 86 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for BNR moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 21 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 70%.
The Moving Average Convergence Divergence Histogram (MACD) for BNR turned negative on October 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 41 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 61 cases where BNR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
BNR moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNR advanced for three days, in 192 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
BNR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 88 of 111 cases where BNR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating fairly steady price growth. BNR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.254) is normal, around the industry mean (66.046). P/E Ratio (-1.142) is within average values for comparable stocks, (2.422). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (1.741) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
ACRS | BNR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 8 | 91 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 30 Undervalued | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 95 | |
PRICE GROWTH RATING 1..100 | 64 | 44 | |
P/E GROWTH RATING 1..100 | 15 | 77 | |
SEASONALITY SCORE 1..100 | 27 | 37 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ACRS's Valuation (30) in the Pharmaceuticals Other industry is in the same range as BNR (49) in the null industry. This means that ACRS’s stock grew similarly to BNR’s over the last 12 months.
ACRS's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as BNR (100) in the null industry. This means that ACRS’s stock grew similarly to BNR’s over the last 12 months.
BNR's SMR Rating (95) in the null industry is in the same range as ACRS (98) in the Pharmaceuticals Other industry. This means that BNR’s stock grew similarly to ACRS’s over the last 12 months.
BNR's Price Growth Rating (44) in the null industry is in the same range as ACRS (64) in the Pharmaceuticals Other industry. This means that BNR’s stock grew similarly to ACRS’s over the last 12 months.
ACRS's P/E Growth Rating (15) in the Pharmaceuticals Other industry is somewhat better than the same rating for BNR (77) in the null industry. This means that ACRS’s stock grew somewhat faster than BNR’s over the last 12 months.
| ACRS | BNR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 77% | 1 day ago 70% |
| Stochastic ODDS (%) | 1 day ago 89% | 1 day ago 80% |
| Momentum ODDS (%) | 1 day ago 87% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 81% | 1 day ago 89% |
| TrendWeek ODDS (%) | 1 day ago 83% | 1 day ago 89% |
| TrendMonth ODDS (%) | 1 day ago 77% | 1 day ago 90% |
| Advances ODDS (%) | 1 day ago 82% | 2 days ago 82% |
| Declines ODDS (%) | 9 days ago 84% | 4 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 78% | 1 day ago 72% |
| Aroon ODDS (%) | 1 day ago 78% | 1 day ago 79% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACRS’s FA Score shows that 1 FA rating(s) are green while BNR’s FA Score has 0 green FA rating(s).
- ACRS’s FA Score: 1 green, 4 red.
- BNR’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACRS’s TA Score shows that 6 TA indicator(s) are bullish while BNR’s TA Score has 5 bullish TA indicator(s).
- ACRS’s TA Score: 6 bullish, 2 bearish.
- BNR’s TA Score: 5 bullish, 4 bearish.
Price Growth
ACRS (@Biotechnology) experienced а +12.72% price change this week, while BNR (@Medical Specialties) price change was -7.53% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.15%. For the same industry, the average monthly price growth was -6.50%, and the average quarterly price growth was +42.74%.
Reported Earning Dates
ACRS is expected to report earnings on Nov 05, 2026.
BNR is expected to report earnings on Nov 19, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Medical Specialties (-3.15% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
ACRS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ACRS has been loosely correlated with CRVS. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if ACRS jumps, then CRVS could also see price increases.
| Ticker / NAME | Correlation To ACRS | 1D Price Change % | ||
|---|---|---|---|---|
| ACRS | 100% | +0.52% | ||
| CRVS - ACRS | 64% Loosely correlated | +5.97% | ||
| STRRP - ACRS | 52% Loosely correlated | +3.16% | ||
| QUCY - ACRS | 40% Loosely correlated | N/A | ||
| UFPT - ACRS | 39% Loosely correlated | +2.49% | ||
| IMNM - ACRS | 38% Loosely correlated | +1.44% | ||
More | ||||
BNR and
Correlation & Price change
A.I.dvisor tells us that BNR and RVTY have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BNR and RVTY's prices will move in lockstep.
| Ticker / NAME | Correlation To BNR | 1D Price Change % | ||
|---|---|---|---|---|
| BNR | 100% | -1.92% | ||
| RVTY - BNR | 25% Poorly correlated | +0.48% | ||
| ACRS - BNR | 24% Poorly correlated | +0.52% | ||
| STXS - BNR | 24% Poorly correlated | +0.31% | ||
| ANGO - BNR | 23% Poorly correlated | +1.09% | ||
| GKOS - BNR | 23% Poorly correlated | -0.09% | ||
More | ||||